argenx: Positive Phase 3 data from thrombocytopenia trial

 Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease severity

Statistically significant separation from placebo in key platelet-derived secondary endpoints

Safety and tolerability profile of VYVGART is consistent with previous clinical trials; ADVANCE is first registrational trial with chronic dosing out to 24 weeks

Topline data expected in first quarter 2023 from ADVANCE-SC, the second pivotal trial required for registration in primary immune thrombocytopenia (ITP)

https://finance.yahoo.com/news/argenx-announces-positive-phase-3-050000275.html